First patient dosed in EVEREST-1 Phase 1 trial of A2B530 (CEA program)
Science
Overview
Technology Platform
Manufacturing
Publications
Pipeline
Overview
Clinical Trials
Overview
About Us
Overview
Leadership
Board of Directors
Scientific Advisory Board
Investors
Partners
Investors
Overview
Newsroom
News
Media Inquiries
Careers
Join the Team
Contact
General Inquires
